We only work on targets and in indications where we believe that Secarna`s LNAplus™ based antisense therapies have the potential to demonstrate superior safety and efficacy benefits over other modalities in development and on the market.
Secarna`s uniquely efficient LNAplus™ discovery process is fueled by our
- proprietary and streamlined Oligofyer™ bioinformatics systems
- large in-house cell library and
- own in vitro screening assays
For subsequent pre-clinical development, Secarna`s molecule design and selection work is complemented by partnerships with internationally renowned centers of excellence across academia and industry.